The fact that endocytosis inhibitor or Mesd overexpression antagonized these adverse effects of oxPLs further supports this concept and implies that manipulation of cell surface LRP6 is a potential strategy for the treatment of osteoporosis. This evidence concerns the gene MESD and osteoporosis.